McN 5707
Mcn 5707 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) designated for the treatment of depression.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Mcn 5707 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.
Binding affinities
Binding affinities (K i ) are: As can be seen, most of the activity resides in a single optical antipode (or enantiomer). Hence, there is a good eudysmic ratio.
SAR
For related agents, see: JNJ-7925476, McN-4612, McN-5292, McN-5558, McN5652, and McN-5908. Other examples of drugs with ortho-chlorophenyl rings include: Ketamine Clofedanol Clortermine Tulobuterol Disobutamide Bidisomide
Text derived from https://en.wikipedia.org/w/index.php?oldid=1337294307 under CC BY-SA 4.0; modifications have been made.